Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A long term follow up study, to evaluate the long term safety and efficacy, of single agent ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours

Next Previous
Search
Trial Profile

A long term follow up study, to evaluate the long term safety and efficacy, of single agent ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATX 101 (Primary) ; Cetirizine; Dexamethasone; Loratadine; Ranitidine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Therapim

    • Most Recent Events

    • 01 Feb 2023 Results(n=25) assessing safety of ATX-101 in patients with advanced solid tumours published in the Oncogene.
    • 03 Mar 2021 Planned End Date changed from 31 Oct 2020 to 30 Jun 2022.
    • 03 Oct 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top